We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs

By LabMedica International staff writers
Posted on 05 Feb 2026

Diagnosing developmental disorders often relies on DNA sequence analysis, but this approach can miss epigenetic context such as DNA methylation, chemical modifications that regulate whether genes are transcribed. When DNA findings are inconclusive, physicians analyze methylation patterns, but this currently requires a separate, specialized test that is not widely available in routine hospital settings.

Researchers from Radboud University Medical Center (Radboud UMC; Nijmegen, Netherlands) now report that an advanced DNA decoding technique known as single long-read sequencing can reliably and effectively map DNA methylation at no additional cost. By combining genetic and epigenetic analysis in one workflow, the method saves time and resources while providing clearer clinical interpretation. Radboud UMC is the first hospital worldwide to implement long-read sequencing at scale as a first-line diagnostic test in routine clinical practice.


Image: Additional insight into DNA methylation could enable more accurate and precise diagnoses (Photo courtesy of Shutterstock)
Image: Additional insight into DNA methylation could enable more accurate and precise diagnoses (Photo courtesy of Shutterstock)

Earlier research had shown that single long-read sequencing provides a more complete view of DNA structure. The latest findings now demonstrate that the method also detects subtle genome-wide differences in methylation, revealing regions with higher or lower methylation levels. These patterns form condition-specific profiles, called episignatures, which allow clinicians to infer the presence of pathogenic DNA changes in specific genes based solely on the methylation profile. The study was published in Genome Medicine on January 26, 2026. 

"Sometimes we find a striking DNA change in a gene, but we’re not sure whether it causes the developmental disorder. In such cases, we can compare the methylation profile with those of other patients known to have the disorder. This helps us determine whether the mutation is truly the cause or not. This leads to more accurate diagnoses," explained study leader Christian Gilissen, Professor of Genome Bioinformatics at Radboud UMC.

Related Links
Radboud UMC


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Homocysteine Quality Control
Liquichek Homocysteine Control

Latest Molecular Diagnostics News

New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
04 Feb 2026  |   Molecular Diagnostics

Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
04 Feb 2026  |   Molecular Diagnostics

Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
04 Feb 2026  |   Molecular Diagnostics